pentamidine has been researched along with Neglected Diseases in 8 studies
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.
Neglected Diseases: Diseases that are underfunded and have low name recognition but are major burdens in less developed countries. The World Health Organization has designated six tropical infectious diseases as being neglected in industrialized countries that are endemic in many developing countries (HELMINTHIASIS; LEPROSY; LYMPHATIC FILARIASIS; ONCHOCERCIASIS; SCHISTOSOMIASIS; and TRACHOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment is stage-specific, due to the blood-brain barrier, with less toxic drugs such as pentamidine used to treat stage 1." | 1.62 | Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug. ( Brown, RC; Burrell-Saward, H; Christie, M; Croft, SL; da Silva, M; Dailey, LA; Dreiss, CA; Fidanboylu, M; Liu, B; Lorenz, C; Persaud, SJ; Sanderson, L; Sekhar, GN; Thomas, SA; Valero, M; Yardley, V, 2021) |
| "Human African trypanosomiasis (HAT, sleeping sickness) ranks among the most neglected tropical diseases based on limited availability of drugs that are safe and efficacious, particularly against the second stage (central nervous system [CNS]) of infection." | 1.42 | Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeys. ( Boykin, DW; Bridges, AS; Brun, R; Ching, S; Gem, CO; Jones, SK; Liu, Q; Murilla, GA; Mutuku, JN; Paine, MF; Thuita, JK; Tidwell, RR; Wang, MZ; Wolf, KK, 2015) |
| " Our compound optimization that has led to synthesis of several potent 4-anilinoquinazolines, including NEU617, 23a, a highly potent, orally bioavailable inhibitor of trypanosome replication." | 1.39 | Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis. ( Behera, R; Edwards, P; Guyett, PJ; Karver, CE; Mensa-Wilmot, K; Patel, G; Pollastri, MP; Roncal, NE; Sullenberger, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, G | 1 |
| Karver, CE | 1 |
| Behera, R | 1 |
| Guyett, PJ | 1 |
| Sullenberger, C | 1 |
| Edwards, P | 1 |
| Roncal, NE | 1 |
| Mensa-Wilmot, K | 1 |
| Pollastri, MP | 1 |
| Mizuno, CS | 1 |
| Souza, AB | 1 |
| Tekwani, BL | 1 |
| Ambrósio, SR | 1 |
| Veneziani, RC | 1 |
| Saad, SM | 1 |
| Ghouri, N | 1 |
| Perveen, S | 1 |
| Khan, KM | 1 |
| Choudhary, MI | 1 |
| Sanderson, L | 1 |
| da Silva, M | 1 |
| Sekhar, GN | 1 |
| Brown, RC | 1 |
| Burrell-Saward, H | 1 |
| Fidanboylu, M | 1 |
| Liu, B | 1 |
| Dailey, LA | 1 |
| Dreiss, CA | 1 |
| Lorenz, C | 1 |
| Christie, M | 1 |
| Persaud, SJ | 1 |
| Yardley, V | 1 |
| Croft, SL | 1 |
| Valero, M | 1 |
| Thomas, SA | 1 |
| Gillingwater, K | 1 |
| Kennedy, PGE | 1 |
| Rodgers, J | 1 |
| Thuita, JK | 1 |
| Wolf, KK | 1 |
| Murilla, GA | 1 |
| Bridges, AS | 1 |
| Boykin, DW | 1 |
| Mutuku, JN | 1 |
| Liu, Q | 1 |
| Jones, SK | 1 |
| Gem, CO | 1 |
| Ching, S | 1 |
| Tidwell, RR | 1 |
| Wang, MZ | 1 |
| Paine, MF | 1 |
| Brun, R | 1 |
| Sbaraglini, ML | 1 |
| Vanrell, MC | 1 |
| Bellera, CL | 1 |
| Benaim, G | 1 |
| Carrillo, C | 1 |
| Talevi, A | 1 |
| Romano, PS | 1 |
2 reviews available for pentamidine and Neglected Diseases
| Article | Year |
|---|---|
Clinical and Neuropathogenetic Aspects of Human African Trypanosomiasis.
Topics: Animals; Antiprotozoal Agents; Blood-Brain Barrier; Brain; Delayed Diagnosis; Humans; Incidence; Neg | 2019 |
Neglected Tropical Protozoan Diseases: Drug Repositioning as a Rational Option.
Topics: Antiprotozoal Agents; Chagas Disease; Drug Repositioning; Humans; Leishmaniasis; Neglected Diseases; | 2016 |
6 other studies available for pentamidine and Neglected Diseases
| Article | Year |
|---|---|
Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Coloring Agents; Drug Design; Drug Discovery; | 2013 |
Synthesis and biological evaluation of polyalthic acid derivatives for the treatment of neglected diseases.
Topics: Antiparasitic Agents; Diterpenes; Inhibitory Concentration 50; Leishmania donovani; Molecular Struct | 2015 |
4-Arylamino-6-nitroquinazolines: Synthesis and their activities against neglected disease leishmaniasis.
Topics: Antiprotozoal Agents; Dose-Response Relationship, Drug; Humans; Leishmania major; Leishmaniasis; Mol | 2016 |
Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug.
Topics: Animals; Blood-Brain Barrier; Female; Humans; Male; Mice; Mice, Inbred BALB C; Neglected Diseases; P | 2021 |
In vitro and in vivo efficacy of diamidines against Trypanosoma equiperdum strains.
Topics: Animals; Disease Models, Animal; Dourine; Drug Resistance; Female; Horse Diseases; Horses; Mice; Neg | 2018 |
Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeys.
Topics: Amidines; Animals; Chlorocebus aethiops; Disease Models, Animal; Furans; Humans; Mice; Neglected Dis | 2015 |